You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 17, 2025

CLINICAL TRIALS PROFILE FOR CYANOCOBALAMIN CO-57


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Cyanocobalamin Co-57

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004495 ↗ Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis Completed Georgetown University N/A 1999-06-01 OBJECTIVES: I. Compare the efficacy of two doses of folic acid in normalizing plasma total homocysteine concentration in patients with end stage renal disease receiving regular hemodialysis therapy resulting in hyperhomocysteinemia. II. Determine the requirement of co-supplementation with extra pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) daily in these patients. III. Assess the safety and tolerability of this therapy in these patients.
NCT00004734 ↗ Vitamin Therapy for Prevention of Stroke Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 3 1996-09-01 A stroke occurs when part of the brain is damaged from lack of normal blood supply. This may result in difficulty with feeling, speech, muscle strength or coordination, movement, thinking, or other brain functions. Having a stroke increases the risk of another stroke occurring in the future. Higher blood levels of a natural chemical known as homocysteine may contribute to hardening of the arteries in the brain or heart and increase the risk of stroke or heart attack. Folic acid, vitamin B6 (pyridoxine), and vitamin B12 (cyanocobalamin) may lower blood levels of homocysteine and reduce the risk of having another stroke or a heart attack.
NCT00032435 ↗ Homocysteine Study (HOST) Completed Abbott Diagnostics Division Phase 3 2001-05-01 The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cyanocobalamin Co-57

Condition Name

Condition Name for Cyanocobalamin Co-57
Intervention Trials
Vitamin B12 Deficiency 3
Anaemia 2
Stroke 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cyanocobalamin Co-57
Intervention Trials
Vitamin B 12 Deficiency 5
Lymphoma 4
Lymphoma, T-Cell 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cyanocobalamin Co-57

Trials by Country

Trials by Country for Cyanocobalamin Co-57
Location Trials
United States 195
India 9
Hungary 7
France 5
Argentina 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cyanocobalamin Co-57
Location Trials
Texas 12
New York 12
California 11
Illinois 11
Pennsylvania 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cyanocobalamin Co-57

Clinical Trial Phase

Clinical Trial Phase for Cyanocobalamin Co-57
Clinical Trial Phase Trials
Phase 4 3
Phase 3 5
Phase 2 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cyanocobalamin Co-57
Clinical Trial Phase Trials
Completed 29
Terminated 3
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cyanocobalamin Co-57

Sponsor Name

Sponsor Name for Cyanocobalamin Co-57
Sponsor Trials
National Cancer Institute (NCI) 8
Spectrum Pharmaceuticals, Inc 7
Acrotech Biopharma LLC 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cyanocobalamin Co-57
Sponsor Trials
Other 32
Industry 19
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Cyanocobalamin Co-57: Clinical Trials, Market Analysis, and Projections

Introduction

Cyanocobalamin Co-57, a radioactive form of vitamin B12, is used primarily for diagnostic purposes, particularly in assessing vitamin B12 absorption and detecting conditions like pernicious anemia. Here, we will delve into the clinical trials, market analysis, and future projections for this drug.

Clinical Use and Pharmacology

Cyanocobalamin Co-57 is administered orally and works by being absorbed in the distal ileum, bound by intrinsic factor, and then utilized in various metabolic processes. It is excreted primarily in the urine, with any unabsorbed portion excreted in the stool[1].

Diagnostic Applications

This radiopharmaceutical is used in tests such as the Schilling test to evaluate vitamin B12 absorption. However, the Schilling test has several limitations, including false-positive results in patients with renal insufficiency and mental disturbances. The plasma test, which measures plasma levels of cyanocobalamin Co-57, is often used as a complementary or alternative method to avoid these issues[4].

Clinical Trials and Safety

Animal Studies and Reproductive Effects

Animal reproduction studies have not been conducted with Cyanocobalamin Co-57 Capsules, and it is not known whether this agent can cause fetal harm or affect reproductive capacity. Therefore, its use in pregnant women is approached with caution, and tests are generally postponed until after delivery unless the potential benefit outweighs the risk[1].

Pediatric and Nursing Mothers

The safety and effectiveness of Cyanocobalamin Co-57 in children have not been established. Additionally, since the drug is excreted in human milk, breastfeeding should be substituted with formula feeding during its use[1].

Market Analysis

Current Market Size and Growth

The global cyanocobalamin market, which includes various forms of vitamin B12, was valued at USD 358.26 million in 2023 and is expected to reach USD 379.29 million in 2024. It is projected to grow at a CAGR of 6.12% to reach USD 543.13 million by 2030[2].

Market Segmentation

The market is segmented by route of administration, end-use, and geographic region. The cyanocobalamin segment, which includes Cyanocobalamin Co-57, holds a major share due to its stability, ease of availability, and cost-effectiveness[3].

Key Drivers

  • Increasing Prevalence of Vitamin B12 Deficiency: Growing health awareness and the rising prevalence of vitamin B12 deficiencies, especially among vegetarians, the elderly, and those with absorption disorders, are driving market growth[2][3].
  • Expanding Geriatric Population: The increasing geriatric population and heightened research into neurodegenerative diseases are fueling demand for cyanocobalamin products[2].
  • Emerging Markets: Regions like Asia-Pacific and Latin America present promising opportunities due to improving healthcare infrastructures and growing nutritional awareness[2].

Key Restraints

  • High Dependency on China: The global market's high dependency on China for cyanocobalamin supply can lead to disruptions in production and supply chains, potentially hampering market growth[3].
  • High Production Costs: The fermentation process required for cyanocobalamin production is costly and time-consuming, contributing to higher market prices[3].

Market Projections

Geographic Trends

  • Asia-Pacific: This region dominated the market in 2023 and is expected to continue growing due to increasing health awareness and improving healthcare infrastructures[3].
  • North America: This region holds a considerable share, driven by the advanced healthcare sector, increased use of dietary supplements, and the prevalence of neural conditions and gastrointestinal issues[3].
  • Europe: Europe is anticipated to grow rapidly, driven by research and innovation in the healthcare and nutrition industry, as well as a high prevalence of pernicious anemia[3].

Future Opportunities

  • Fortified Foods and Beverages: The trend of fortifying vitamins and minerals in food products, especially among vegetarians, is expected to drive market growth[3][5].
  • Pharmaceutical and Functional Foods: The introduction of new pharmaceutical and functional food products containing cyanocobalamin will continue to propel market demand[3].

Key Takeaways

  • Clinical Use: Cyanocobalamin Co-57 is primarily used for diagnosing vitamin B12 absorption defects and has specific clinical applications.
  • Market Growth: The global cyanocobalamin market is expected to grow at a CAGR of 6.12% until 2030, driven by increasing health awareness and the prevalence of vitamin B12 deficiencies.
  • Geographic Trends: Asia-Pacific, North America, and Europe are key regions driving market growth due to various factors including healthcare infrastructure and nutritional awareness.
  • Challenges: High dependency on China for supply and high production costs are significant restraints to market growth.

FAQs

What is Cyanocobalamin Co-57 used for?

Cyanocobalamin Co-57 is used primarily for diagnostic purposes, particularly in assessing vitamin B12 absorption and detecting conditions like pernicious anemia.

What are the key drivers of the cyanocobalamin market?

Key drivers include the increasing prevalence of vitamin B12 deficiencies, the expanding geriatric population, and growing health awareness and nutritional trends.

What are the main restraints to the cyanocobalamin market?

High dependency on China for supply and high production costs due to the fermentation process are significant restraints.

Which regions are expected to drive market growth?

Asia-Pacific, North America, and Europe are expected to drive market growth due to improving healthcare infrastructures, advanced healthcare sectors, and growing nutritional awareness.

What are the future opportunities for the cyanocobalamin market?

Future opportunities include the growth in fortified foods and beverages, and the introduction of new pharmaceutical and functional food products containing cyanocobalamin.

Sources

  1. Rubratope-57 Cyano Capsule Package Insert. University of New Mexico.
  2. Cyanocobalamin Market by Route of Administration, End-use. 360iResearch.
  3. Vitamin B12 Market Size, Share, Growth | Industry Report [2032]. Fortune Business Insights.
  4. Comparison of Schilling Test and Plasma Level of Cyanocobalamin. JAMA Network.
  5. Cyanocobalamin Injection Market Size and Growth Analysis By 2030. Allied Market Research.
Last updated: 2025-01-07

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.